Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Comparing the brief Holistic Health for HIV (3H+) to the Holistic Health Recovery Program (HHRP+) among people with HIV and opioid use disorder: Results from a randomized, controlled non-inferiority trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
    • نبذة مختصرة :
      Few evidence-based interventions have been widely adopted in common clinical settings, particularly for opioid-dependent people with HIV (PWH) seeking drug treatment. We developed a brief evidence-based intervention, Holistic Health for HIV (3H+), specifically for ease of implementation and integration within drug treatment settings. In this study, we compared 3H+ to the gold standard, Holistic Health Recovery Program (HHRP+) using a non-inferiority trial. Between 2012 and 2017, 106 participants were randomly assigned to either the brief 3H+ intervention or the gold standard HHRP+. HIV treatment (ART adherence, viral suppression) and risk behaviors (sharing injection equipment, condom use) were compared between the two arms at baseline, end-of-intervention (EOI-12 weeks) and at follow-up (24 weeks). Average treatment effect was calculated based on the difference-in-difference (DID) estimator and a non-parametric bootstrap was used to assess non-inferiority. At the 12-week EOI point, 3H+ was found to be non-inferior to HHRP+ with respect to multiple outcomes: percent sharing syringes and needles (DID:1.4, 95%CI [-18.6,21.5], p<0.01) and attainment of high ART adherence (DID: 9.7, 95%CI: [-13.1, 32.2], p = 0.04). At the 24-week EOI point, 3H+ was found to be non-inferior to HHRP+ with respect to percent sharing syringes and needles (DID: 8.9, [-10.1, 28.30], p = 0.04) and attainment of viral suppression (DID: 18.9, 95% CI:[-7.1, 42.0], p = 0.01). For other indicators, such as consistent condom use, the hypothesis test for non-inferiority was inconclusive at the 12-week EOI (DID: -20.2, 95%CI [-48.9-10.7], p = 0.51). For HIV treatment as prevention to be effective, PWH need to achieve viral suppression. In the absence of this success, they must reduce HIV risk behaviors. The finding that 3H+ was non-inferior to HHRP+ suggests that brief behavioral interventions can be deployed in real world settings to help more efficiently achieve Ending the HIV Epidemic goals.
      Competing Interests: The authors have declared that no competing interests exist.
      (Copyright: © 2024 Zelenev et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Curr HIV/AIDS Rep. 2018 Apr;15(2):96-112. (PMID: 29460225)
      Psychol Addict Behav. 2001 Jun;15(2):83-8. (PMID: 11419234)
      Mayo Clin Proc. 2020 Dec;95(12):2709-2718. (PMID: 33276843)
      Ann Med. 2022 Dec;54(1):1714-1724. (PMID: 35775786)
      Science. 1998 May 8;280(5365):867-73. (PMID: 9572724)
      Psychiatr Serv. 2022 Apr 01;73(4):411-417. (PMID: 34407631)
      J Subst Abuse Treat. 2006 Sep;31(2):163-71. (PMID: 16919744)
      Int J Drug Policy. 2014 Jan;25(1):34-52. (PMID: 23973009)
      J Neurovirol. 2007 Jun;13(3):203-9. (PMID: 17613710)
      Subst Abus. 2011 Jan;32(1):16-26. (PMID: 21302180)
      Clin Infect Dis. 2007 Dec 15;45 Suppl 4:S300-307. (PMID: 18190303)
      Am J Public Health. 2012 Nov;102(11):e34-44. (PMID: 22994247)
      Stat Med. 2011 Feb 20;30(4):377-99. (PMID: 21225900)
      Cogn Behav Therap. 2020 May 04;13:e14. (PMID: 34191937)
      Psychol Bull. 1992 May;111(3):455-74. (PMID: 1594721)
      Am J Public Health. 2010 Nov;100(11):2193-8. (PMID: 20167901)
      Contemp Clin Trials. 2015 Sep;44:95-102. (PMID: 26253181)
      AIDS Behav. 2022 Apr;26(4):1047-1055. (PMID: 34510289)
      Health Psychol. 2003 Mar;22(2):223-8. (PMID: 12683743)
      Am J Public Health. 2009 Nov;99(11):2069-78. (PMID: 19762676)
      Stat Med. 2003 Jan 30;22(2):169-86. (PMID: 12520555)
      Int J Eat Disord. 2020 Jul;53(7):1132-1141. (PMID: 32383530)
      Public Health Rep. 1996 May-Jun;111(3):276-9. (PMID: 8643822)
      Health Promot Pract. 2011 Jan;12(1):25-35. (PMID: 19858321)
      J Urban Health. 2006 Nov;83(6):1132-42. (PMID: 16933102)
      J Consult Clin Psychol. 2005 Feb;73(1):106-15. (PMID: 15709837)
      Br J Clin Pharmacol. 2017 Aug;83(8):1636-1642. (PMID: 28252213)
      Int J Drug Policy. 2022 Mar;101:103570. (PMID: 34954493)
      AIDS Behav. 2021 Jul;25(7):2230-2239. (PMID: 33449236)
      Lancet. 2021 Mar 20;397(10279):1139-1150. (PMID: 33617769)
      Health Psychol. 2006 Jul;25(4):462-73. (PMID: 16846321)
      MMWR Morb Mortal Wkly Rep. 2019 Mar 15;68(10):253-254. (PMID: 30870405)
      J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):288-295. (PMID: 30312275)
      AIDS Behav. 2022 Jan;26(1):277-283. (PMID: 34287755)
      Trials. 2011 May 03;12:106. (PMID: 21539749)
      MMWR Morb Mortal Wkly Rep. 2015 May 1;64(16):443-4. (PMID: 25928470)
      Front Public Health. 2014 Aug 11;2:105. (PMID: 25157345)
      J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):154-62. (PMID: 21725250)
      AIDS. 2012 Mar 13;26(5):529-32. (PMID: 22210638)
      Implement Sci. 2018 Sep 26;13(1):125. (PMID: 30257683)
      J Acquir Immune Defic Syndr. 2008 Mar 1;47 Suppl 1:S40-6. (PMID: 18301133)
      Clin Infect Dis. 2016 Oct 15;63(8):1094-1104. (PMID: 27343545)
    • Grant Information:
      T32 DA019426 United States DA NIDA NIH HHS
    • الموضوع:
      Date Created: 20241107 Date Completed: 20241107 Latest Revision: 20241121
    • الموضوع:
      20241121
    • الرقم المعرف:
      PMC11542883
    • الرقم المعرف:
      10.1371/journal.pone.0312165
    • الرقم المعرف:
      39509356